3 ms·
The paper SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 [1] comes out of Ralph Baric's lab: > Here we used a single experimental platf
by sradman 6y ago
The paper SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 [1] comes out of Ralph Baric's lab:
> Here we used a single experimental platform based on human lung-only mice (LoM) to demonstrate efficient in vivo replication of all recently emerged human coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2) and two highly relevant endogenous pre-pandemic SARS-like bat coronaviruses.
> Our results show that therapeutic and prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently in phase II–III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and thus has significant potential for the prevention and treatment of COVID-19.
EIDD-2801 (Molnupiravir [2]) is an oral antiviral while monoclonal antibody treatment requires intravenous delivery.
[1] https://www.nature.com/articles/s41586-021-03312-w https://www.nature.com/articles/s41586-021-03312-w
[2] https://en.wikipedia.org/wiki/Molnupiravir https://en.wikipedia.org/wiki/Molnupiravir